Production (Stage)
Integrated Biopharma, Inc.
INBP
$0.29
-$0.0135-4.45%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.57% | -7.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.57% | -7.37% | |||
| Cost of Revenue | 8.33% | -6.56% | |||
| Gross Profit | 32.45% | -14.59% | |||
| SG&A Expenses | -16.20% | 9.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.41% | -5.45% | |||
| Operating Income | 265.84% | -58.78% | |||
| Income Before Tax | 320.54% | -63.29% | |||
| Income Tax Expenses | 142.03% | -71.84% | |||
| Earnings from Continuing Operations | 426.72% | -55.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 426.72% | -55.21% | |||
| EBIT | 265.84% | -58.78% | |||
| EBITDA | 185.96% | -50.69% | |||
| EPS Basic | 431.58% | -55.81% | |||
| Normalized Basic EPS | 247.73% | -58.10% | |||
| EPS Diluted | 440.54% | -56.98% | |||
| Normalized Diluted EPS | 244.19% | -58.25% | |||
| Average Basic Shares Outstanding | 0.42% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.68% | 2.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||